An observational study in Covid19, ME/CFS and SARS COV2, sponsored by Rush University Medical Center. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-14.
Sponsored by Rush University Medical Center · Observational
The Innovative Support for Patients with SARS COV-2 Infections Registry (INSPIRE) study is a CDC-funded COVID-19 project to understand the long-term health outcomes in recently tested adults, both negative and positive, who have suspected COVID symptoms at the time of their test. Participants will complete short online surveys every 3 months for 18 months, share information about their health using a secure web-based platform, and are compensated for their time.
This study will use a digital platform to longitudinally track comprehensive information including patient self-report as well as data that describe the process and outcome of care in the electronic medical record (EMR) of a large representative sample of patients under investigation for SARSCOV2. The objective is to generate knowledge rapidly using digital tools and collaborative sciences to produce real-time data, analysis, and reporting compared to more traditional approaches. An additional goal is to promote an open science approach whereby scientists, with proper approvals and in line with the permissions granted by the participants, have the opportunity to work with data in ways that protect individual privacy but promote rapid dissemination and implementation of knowledge.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 6,000 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Rush University Medical Center is the lead sponsor of 394 studies on the registry; 61 are open to participants now.
Of its 30 completed or terminated interventional studies of FDA-regulated products, 25 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adults aged>=18, with symptoms consistent with infection with SARS-COV2; test positive vs test negative individuals will be enrolled at a rate of 3:1.
EXCLUSION CRITERIA
Symptomatic Individuals test positive for SARS-COV2. Participants will be enrolled soon after infection and followed to assess for long term outcomes.
Symptomatic Individuals test negative for SARS-COV2. Participants will be enrolled soon after testing and followed to assess for long term outcomes.
Assess for medium and long-term sequalae of SARS-CoV-2 infection
Clinical phenotypes of sequelae will be determined at the time of analysis based on published literature
Time frame: 18 months post enrollment
Incident myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Determine the risk of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in those with symptoms of SARSCOV2 infection with vs. without a positive confirmatory test.
Time frame: 18 months post enrollment
Ambulatory care and/or ED visits post enrollment
Count of ambulatory care and/or ED visits post enrollment as obtained from the EMR
Time frame: 18 months post enrollment
Hospitalizations post enrollment
Count of hospitalizations post enrollment as obtained from the EMR
Time frame: 18 months post enrollment
Death during hospital admission
Death during hospital admission as determined by data from the EMR
Time frame: 18 months post enrollment
Hospital-free survival
Hospital-free survival as determined by data from the EMR
Time frame: 18 months post enrollment
ICU-free survival
ICU-free survival as determined by data from the EMR
Time frame: 18 months post enrollment
Plan to share: No
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rush University Medical Center